Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The approval marks a major milestone in the global fight against antimicrobial resistance
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
